Abstract
- Population : Immunocompetent children aged 3–24 months
- Intervention: One or two doses of MenA conjugate vaccine (5 µg dosage)
- Comparison: No MenA vaccination
- Outcome : Serogroup A meningococcal disease
What is the evidence of long-term protection against serogroup A meningococcal disease following vaccination with one or two doses of MenA conjugate vaccine in immunocompetent children aged 3–24 months?
GRADE table
Newborn
GRADE
Meningococcal disease
